Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00960804 · ClinicalTrials.gov registry record · Phase 3
Long-Term Study Of The Safety Of Tanezumab In Arthritis Patients
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 21
- Enrollment target
NCT00960804 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 21 participants.
The verdict
NCT00960804, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 21 participants
- Enrollment target
Study Summary
Tanezumab, administered for up to 1 1/2 years, reduces the pain of osteoarthritis without affecting how nerve impulses are transmitted in sensory nerves
Interventions
- OTHER Placebo
- BIOLOGICAL Tanezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2010-02-15 |
| Est. Completion | 2010-11-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00960804
The ClinicalTrials.gov registry entry for NCT00960804 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00960804 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00960804 about?
NCT00960804 is a clinical study titled "Long-Term Study Of The Safety Of Tanezumab In Arthritis Patients". Tanezumab, administered for up to 1 1/2 years, reduces the pain of osteoarthritis without affecting how nerve impulses are transmitted in sensory nerves
What is the current status of trial NCT00960804?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 21 participants. The study started on 2010-02-15. Estimated completion is 2010-11-11.
What interventions are being tested in trial NCT00960804?
The interventions under investigation include: Placebo (OTHER), Tanezumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00960804?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.